Lebwohl MG, Blauvelt A, Menter A, et al. - Among individuals with moderate-to-severe plaque psoriasis, researchers tested the long-term safety and effectiveness of brodalumab, a fully human anti-interleukin-17 receptor A monoclonal antibody. In an open-label extension study, patients who completed a 12-week, phase II, dose-ranging clinical trial received brodalumab 210 mg every 2 weeks. Overall, for a median of 264 weeks, 181 individuals received brodalumab. Over 5 years of treatment, brodalumab showed skin clearance and improved quality of life with an appropriate safety profile. One adverse suicidal ideation event has been reported over 5 years, no suicides have occurred, and no new safety signals have emerged.